(0.11%) 5 186.21 points
(0.04%) 38 870 points
(-0.06%) 16 339 points
(0.18%) $78.62
(0.68%) $2.21
(-0.36%) $2 322.90
(-0.32%) $27.53
(2.44%) $988.45
(0.18%) $0.930
(0.86%) $10.92
(0.44%) $0.799
(-0.05%) $91.30
Live Chart Being Loaded With Signals
Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide...
Stats | |
---|---|
今日成交量 | 2.76M |
平均成交量 | 5.12M |
市值 | 1.26B |
EPS | HKD0 ( 2023-08-29 ) |
下一个收益日期 | ( HKD0 ) 2024-06-26 |
Last Dividend | HKD0.0100 ( 2021-06-16 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -3.93 |
ATR14 | HKD0.00400 (0.68%) |
音量 相关性
VIVA Biotech Holdings 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
VIVA Biotech Holdings 相关性 - 货币/商品
VIVA Biotech Holdings 财务报表
Annual | 2023 |
营收: | HKD2.16B |
毛利润: | HKD738.43M (34.26 %) |
EPS: | HKD-0.0598 |
FY | 2023 |
营收: | HKD2.16B |
毛利润: | HKD738.43M (34.26 %) |
EPS: | HKD-0.0598 |
FY | 2022 |
营收: | HKD2.38B |
毛利润: | HKD815.68M (34.28 %) |
EPS: | HKD-0.280 |
FY | 2021 |
营收: | HKD2.10B |
毛利润: | HKD650.98M (30.94 %) |
EPS: | HKD0.150 |
Financial Reports:
No articles found.
VIVA Biotech Holdings Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
First Dividend | HKD0.00500 | 2019-09-09 |
Last Dividend | HKD0.0100 | 2021-06-16 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 4 | -- |
Total Paid Out | HKD0.0470 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.9 | -- |
Div. Sustainability Score | 7.09 | |
Div.Growth Potential Score | 1.982 | |
Div. Directional Score | 4.54 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
6881.HK | Ex Dividend Knight | 2023-07-11 | Annually | 0 | 0.00% | |
1977.HK | Ex Dividend Knight | 2023-09-11 | Semi-Annually | 0 | 0.00% | |
1001.HK | Ex Dividend Junior | 2023-08-24 | Annually | 0 | 0.00% | |
0104.HK | Ex Dividend Knight | 2023-08-16 | Sporadic | 0 | 0.00% | |
3369.HK | Ex Dividend Knight | 2023-07-11 | Annually | 0 | 0.00% | |
1579.HK | Ex Dividend Knight | 2023-05-22 | Annually | 0 | 0.00% | |
0604.HK | Ex Dividend Junior | 2023-06-02 | Semi-Annually | 0 | 0.00% | |
9918.HK | Ex Dividend Junior | 2023-06-06 | Annually | 0 | 0.00% | |
2161.HK | Ex Dividend Junior | 2023-08-15 | Annually | 0 | 0.00% | |
1157.HK | Ex Dividend Junior | 2023-07-03 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0539 | 1.500 | -1.077 | -1.616 | [0 - 0.5] |
returnOnAssetsTTM | -0.0156 | 1.200 | -0.520 | -0.623 | [0 - 0.3] |
returnOnEquityTTM | -0.0317 | 1.500 | -1.463 | -2.19 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.324 | 0.800 | 8.38 | 6.70 | [1 - 3] |
quickRatioTTM | 0.941 | 0.800 | 9.17 | 7.34 | [0.8 - 2.5] |
cashRatioTTM | 0.675 | 1.500 | 7.36 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.255 | -1.500 | 5.74 | -8.61 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.447 | 2.00 | 9.85 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.228 | 2.00 | 9.89 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.516 | -1.500 | 7.94 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.343 | 1.000 | 7.62 | 7.62 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0894 | 1.000 | -0.212 | -0.212 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.201 | 1.000 | 9.99 | 9.99 | [0.2 - 2] |
assetTurnoverTTM | 0.289 | 0.800 | -1.404 | -1.124 | [0.5 - 2] |
Total Score | 7.09 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -4.36 | 1.000 | -0.541 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0317 | 2.50 | -0.941 | -2.19 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.228 | 2.00 | 9.92 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.447 | 2.00 | 9.85 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0344 | 1.500 | -3.56 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.178 | 1.000 | 8.05 | 0 | [0.1 - 0.5] |
Total Score | 1.982 |
VIVA Biotech Holdings
Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody drug research and development services, include antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, antibody characteristics, and antibody cell line engineering transformation, as well as offers technology platforms, such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS, crystal structure determination of protein, and SPR technology. It also provides cell lines, crystal structures, GPCR proteins, antibodies, and proteins. In addition, the company offers contract development and manufacturing services for small molecule active pharmaceutical ingredients (APIs) and intermediates; and trades in APIs, intermediates, and formulations, as well as equity for service. Further, it provides research service; laboratory rental services; and project management and bidding services, as well as sells compounds. The company was incorporated in 2008 and is headquartered in Shanghai, China.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。